Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00954174 · OUTCOME

Overall Survival

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer · Source last updated 2021-09-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 115 months.

What was measured

Measured in months from randomization to last contact or death. Primary analysis was restricted to the eligible uterine carcinosarcoma cohort.

Analysis population: All eligible patients

Groups in this outcome

Regimen I- Uterine Carcinsarcoma Subjects

Paclitaxel 175 mg/m2 IV over 3 hours Day 1 Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles

Regimen II - Uterine Carcinsarcoma Subjects

Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen I- Uterine Carcinsarcoma Subjects228
Regimen II - Uterine Carcinsarcoma Subjects221

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Regimen I- Uterine Carcinsarcoma Subjects37.3Not reported25.749.0Not reported
Regimen II - Uterine Carcinsarcoma Subjects29Not reported21.943.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        25.7
        upper Limit
        49.0
        value
        37.3
      2. group Id
        OG001
        lower Limit
        21.9
        upper Limit
        43.1
        value
        29
denoms
  1. counts
    1. group Id
      OG000
      value
      228
    2. group Id
      OG001
      value
      221
    units
    Participants
description
Measured in months from randomization to last contact or death. Primary analysis was restricted to the eligible uterine carcinosarcoma cohort.
dispersion Type
95% Confidence Interval
groups
  1. description
    Paclitaxel 175 mg/m2 IV over 3 hours Day 1 Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles
    id
    OG000
    title
    Regimen I- Uterine Carcinsarcoma Subjects
  2. description
    Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6
    id
    OG001
    title
    Regimen II - Uterine Carcinsarcoma Subjects
param Type
MEDIAN
population Description
All eligible patients
reporting Status
POSTED
time Frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 115 months.
title
Overall Survival
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice